EDMONTON, Sept. 5 /CNW/ - It is well known that many cancer types - or
even the same cancer in different patients - show different sensitivities to a
given therapeutic treatment. In earlier studies Cyplasin-SC(TM) has shown to
be an efficient killer of many cancer cell types whereas normal human cells
were left intact. An independent third party study conducted by Professor di
Liegro, Department of Medicine of the University of Palermo, Italy, tested
Cyplasin-SC(TM) on 5 melanoma cell lines derived from 5 different patients to
determine if all melanoma cells were equally susceptible to Cyplasin-SC(TM) or
if there were specific melanomas that did not respond to the drug. As a
control to these experiments normal human cells were also exposed to the same
concentrations of Cyplasin-SC(TM) used for the melanoma experiments.
